AQX-1125

AQX-1125 is the company's most advanced product and was selected as the lead product because it is a potent activator of SHIP1. AQX-1125 is being developed for the treatment of blood and immune disorders and has many desirable drug attributes that make it especially compelling:

• it is highly selective for SHIP1
• it is a small molecule (<500 daltons)
• it has a scalable synthesis
• it has shown potent anti-inflammatory activity both in vitro and in vivo
• it can be dosed once-a-day orally
• it has excellent pharmaceutical properties